PMID

Data

Article Title

Organization

Inhibition of the ß-class carbonic anhydrases from Mycobacterium tuberculosis with carboxylic acids.

Universit?? Degli Studi Di Firenze

The SUMO1-E67 interacting loop peptide is an allosteric inhibitor of the dipeptidyl peptidases 8 and 9.

Georg-August-University Of Goettingen

Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages.

University Of Queensland

Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.

Purdue University

Achiral oligoamines as versatile tool for the development of aspartic protease inhibitors.

Philipps University Marburg

Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.

Purdue University

Flexible cyclic ethers/polyethers as novel P2-ligands for HIV-1 protease inhibitors: design, synthesis, biological evaluation, and protein-ligand X-ray studies.

Purdue University

Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S.

Georgia State University

Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.

Johnson & Johnson Pharmaceutical

Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.

University Of Queensland

Structure-Based Design of Novel HIV-1 Protease Inhibitors To Combat Drug Resistance.

Purdue University

New, potent P1/P2-morpholinone-based HIV-protease inhibitors.

Glaxosmithkline

Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.

Ambrilia Biopharma

Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.

Pharmacor

Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-disubstituted ureas.

Procyon Biopharma

Lysine sulfonamides as novel HIV-protease inhibitors: optimization of the Nepsilon-acyl-phenyl spacer.

Pharmacor

1,2,5,6-tetra-O-benzyl-D-mannitol derivatives as novel HIV protease inhibitors.

Pharmacor

Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2' structure-activity relationship, and molecular recognition of cyclic ureas.

Dupont Pharmaceuticals

Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.

Purdue University

Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere.

University Of Illinois At Chicago

Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.

University Of Illinois At Chicago

Novel cyclourethane-derived HIV protease inhibitors: a ring-closing olefin metathesis based strategy.

University Of Illinois At Chicago

Novel spirocyclic pyrrolidones as P2/P1 mimetics in potent inhibitors of HIV-1 protease.

Glaxosmithkline

Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.

Glaxosmithkline

Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.

Glaxosmithkline

Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.

Glaxosmithkline

Optimization of pyrrolidinone based HIV protease inhibitors.

Glaxosmithkline

Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors.

Glaxosmithkline

Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.

Georgia State University

An ethylenamine inhibitor binds tightly to both wild type and mutant HIV-1 proteases. Structure and energy study.

Academy Of Sciences Of The Czech Republic

Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.

University Of Florida College Of Medicine

Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors.

University Of Pennsylvania

Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors.

Uppsala University